Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (52)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Sugimura, H.
Right arrow Articles by Harris, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sugimura, H.
Right arrow Articles by Harris, C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 Oxford University Press

research-article

Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls

Haruhiko Sugimura, Neil E. Caporaso 1, Gail L. Shaw 1, Rama V. Modali, Frank J. Gonzalez 2, Robert N. Hoover 1, James H. Resau 3, Benjamin F. Trump 3, Ainsley Weston and Curtis Harris 4

Laboratory of Human Carcinogenesis NCI, NIH, Bethesda, MD 20892
1Environmental Epidemiology Branch NCI, NIH, Bethesda, MD 20892
2Laboratory of Molecular Carcinogenesis NCI, NIH, Bethesda MD 20892
3Department of Pathology, University of Maryland Baltimore, MD 21201, USA

4To whom correspondence and reprint requests should be addressed

The extensive metabolize phenotype of debrisoquine has been associated with increased risk of lung cancer, and it has been proposed that a molecular test for this phenotype is feasible. DNA restriction fragment length polymorphisms of the human dehrisoquine 4-hydroxylase gene locus (CYP2D6), and the metabolic phenotype for debrisoquine have been studied in a group of healthy volunteers, a group of lung cancer patients and two control groups (chronic obstructive pulmonary disease patients and patients with cancers at sites other than the lung). Confirmation of four distinct XbaI allelic fragments (44, 29, 16/9 and 11.5 kb), previously identified among caucasians, was obtained. The29 kb alleles were the most frequently observed In both poor and extensive metabolizers of debrisoquine. Alleles of 44 kb were found with approximately equal frequency among both poor and extensive metabolizers. The data are consistent with thehypothesis that the 11.5 and 44 kb fragments are associated with mutant alleles of the CYP2D6 gene, but the power of phenotype prediction by these alleles was less than that previously reported for a European (Swiss-German) population. Similarly, the data also show that 8% of 29 homozygotes are poor metabolizers (indicating that at least 28% of 29 kb fragments are also associated with mutant alleles) and are not therefore informative for predicting the debrisoquine phenotype. The 16/9 allele may represent either wild-type or mutant alleles. Restriction fragments of 44 were found more frequently among cancer patients and chronic obstructive pulmonary disease patients (30%) than among the healthy volunteer group (7%) Genotypes observed were not related to lung tumor histology. Furthermore, least three EcoRI alleles were found to be in linkage disequilibrium with the ‘mutant’ 44 kb allele. These data suggest that the 44 kb allele can comprise three distinct haplotypes, in contrast to studies of a European population. These studies indicate that no single mutant CYP2D6 allele as determined by EcoRI appears to be associated with lung cancer, despite the findings that these patients are invariably of the extensive metaholizer phenotype.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Hum Mol GenetHome page
J. Sarmanova, K. Benesova, I. Gut, V. Nedelcheva-Kristensen, L. Tynkova, and P. Soucek
Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas
Hum. Mol. Genet., June 1, 2001; 10(12): 1265 - 1273.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
B. F. Trump
Molecular Mechanisms of Genetic Deregulation in Toxicity and Carcinogenesis July 20-25, 1991, The Gant Conference Center, Aspen, Colorado: Program and Abstracts
Toxicol Pathol, January 1, 1991; 19(4-2): 625 - 669.
[PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.